Casirivimab-imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: An Early Experience

Transplantation. 2021 Jul 1;105(7):e68-e69. doi: 10.1097/TP.0000000000003737.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antiviral Agents / therapeutic use*
  • COVID-19 / etiology
  • COVID-19 Drug Treatment*
  • Drug Combinations
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Organ Transplantation*
  • Postoperative Complications / drug therapy*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Drug Combinations
  • casirivimab and imdevimab drug combination